A signature for success
A team led by Ludwig and Memorial Sloan Kettering (MSK) researchers has published a landmark study on the genetic basis of response to a powerful cancer therapy known as immune checkpoint blockade. Their paper describes the precise genetic signatures in melanoma tumours that determine whether a patient will respond to one such therapy. It also […]
